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ANTI-VASCULOGENIC EFFECT OF MYCOPHENOLIC ACID 
 
Patients with chronic inflammatory rheumatic disease (CIRD) manifest prominent 
systemic and local vascular damage. Prolonged inflammation results in widespread 
endothelial dysfunction with subsequent development of atherosclerosis and premature 
cardiovascular disease that is becoming prevalent in patients with rheumatic disease. 
Although inflammation occurs primarily at the endothelium-leukocyte interface, very little 
is known about the intrinsic vasculoreparative properties of the damaged endothelium. 
Circulating and tissue resident vascular endothelial progenitor cells (EPC) are believed 
to participate in repairing the damaged endothelium and maintaining the integrity of the 
vascular lining. Endothelial colony forming cells (ECFC) are rare, viable, circulating cells 
that display properties consistent with those of a progenitor cell have been identified in 
humans. Alterations in the function of ECFC results in impaired vessel repair 
mechanisms. In this work, we sought to determine the effects of a commonly used 
immunosuppressive drug, mycophenolic acid (MPA), in treatment of CIRD. MPA inhibits 
ECFC proliferation in a dose dependent fashion, blunts cell migration, and reduces 
ECFC vasculogenic function. Consequently, MPA could contribute to endothelial 
damage in many rheumatic diseases associated with vascular pathology.  
The ATP-binding cassette transporter subfamily G member 2 (Abcg2), a cell surface 
marker for stem cell isolation in multiple lineages. Yoder/Basile lab showed that Abcg2 is 
highly expressed in tissue vascular EPC using knock-in mice for a tamoxifen-inducible 
Abcg2 promoter driven Cre recombinase with ROSATdTomato transgenic reporter mice. 
Preliminary work shows that murine blood vessels contain Abcg2-expressing endothelial 
cells that contribute to heart and kidney vessel growth during development, and 
vii 
maintenance of kidney vessel homeostasis in adults in vivo. Systemic lupus 
erythematosus (SLE) is a type of CIRD that is characterized by microvascular 
inflammation and damage, endothelial dysfunction and increased cardiovascular risk. 
Future studies are directed towards identifying how lupus-associated factors and 
mycophenolic acid influence Abcg2-expressing endothelial cell properties using a well-
described pristane-induced lupus mouse model. 
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CHAPTER I 
1.1 INTRODUCTION 
Chronic inflammatory rheumatic diseases (CIRD) are a group of heterogeneous but 
related disorders, some of which include systemic lupus erythematosus, juvenile 
dermatomyositis, systemic sclerosis and systemic vasculitis. Despite having varied 
clinical manifestations, they all share a common pathologic feature of inflammation 
mediated by leukocytes at the interface with the lining of blood vessels. Vascular lesions 
can be the result of vasculitis (transmural inflammation of the blood vessel wall), or 
vasculopathy, (non-transmural injury to the vessels that is not the result of primary 
vessel wall inflammation), like thromboembolic disease, coagulative disorder or other 
forms of vessel injury. Any vessel type can be involved and thus vasculopathy can result 
in varied phenotypic expression, anywhere from mild cutaneous lesions (rash) to 
systemic features that compromise the integrity and function of any organ. 
 
1.2 VASCULAR INVOLVEMENT IN CIRD 
1.2.1 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)  
SLE is a prototypic systemic autoimmune condition mediated by immune-complex 
induced inflammation. Vascular lesions are among the most characteristic features of 
SLE and have a prevalence that ranges between 10-40% of SLE patients [1-3]. They 
may precede the development of full-blown disease and play a key role in the choice of 
treatment strategy and prognosis. Vascular injury in lupus can cause lupus vasculopathy 
(vascular wall necrosis and a thrombus in the lumen of an affected artery), lupus 
vasculitis with inflammation, necrotizing lesions, thrombotic microangiopathy, and 
atherosclerosis [4, 5]. Cutaneous microangiopathy, classified as small-vessel 
involvement, are the most common representing 90% [2, 6]; however, widespread, 
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necrotizing visceral medium-and large-vessel involvement that affects the heart, lungs 
brain and kidney, may also occur.  
 
1.2.2 JUVENILE DERMATOMYOSITIS (JDM) 
JDM is an autoimmune condition of childhood that is characterized by small vessel 
vasculopathy affecting the skin and musculature but can involve the heart, lungs and 
gastrointestinal tract as well. Although classified as an inflammatory myopathy, JDM 
displays prominent vascular and perivascular inflammation that contributes directly to the 
clinical features and outcome of the disease [7-9]. Biopsy of involved areas reveals 
extensive reduction in capillary density, endothelial antibody deposition and complement 
activation that leads to endothelial dysfunction, endothelial release of pro-inflammatory 
cytokines and upregulation of adhesion molecules [7, 10-13].  
 
1.2.3    SYSTEMIC SCLEROSIS (SSc)  
SSc is a connective tissue disease characterized by inflammation, vasculopathy and 
progressive fibrosis of the skin, lungs and other tissues. SSc is considered a fibrosing 
disease, but vascular involvement plays a major role in pathogenesis and organ 
dysfunction. Autopsy studies showed that SSc patients have widespread intimal 
proliferation of small and/or large arteries in the pulmonary, coronary, and renal 
circulation [14].The initial vascular injury from autoimmune or environmental factors 
cause endothelial cell dysregulation vacuolization of endothelial cell cytoplasm, and loss 
of membrane-bound storage vesicles [15-17]. Vasculopathy then ensues resulting from 
abnormal vasoreactivity, tissue hypoxia, dysregulation of coagulation, fibrinolytic 
processes, and/or direct structural damage [18-20]. Impaired compensatory 
vasculogenesis and angiogenesis plays an important role in the fibroproliferative 
vasculopathy observed in SSc [16, 19, 21].   
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1.2.4 PRIMARY SYSTEMIC VASCULITIS (PSV) 
PSV is a group of multisystem disorders in which the blood vessels are the major 
disease target with no other underlying disease and thus, endothelial dysfunction is 
inherent in these diseases. Disease classification is based on the size of affected 
vessels; the clinical presentation depends on the site, type and size of vessels involved 
[22, 23]. Some of the acute primary vasculitis disorders are common pediatric diseases 
like Henoch-Schonlein purpura and Kawasaki disease, while others are rare like ANCA-
associated vasculitis and Takayasu disease [24]. The pathogenesis underlying these 
inflammatory conditions include cell-mediated inflammation, immune complex-mediated 
inflammation and autoantibody driven but the central histological feature involves 
endothelial activation leading to massive inflammatory cell infiltration along the vessel 
wall, necrosis, thrombosis, aneurysm or vascular narrowing [25, 26].  
 
1.3 CARDIOVASCULAR DISEASE IN CIRD 
CIRD has been linked to cardiovascular disorders, with a markedly increased risk of 
cardiovascular disease (CVD) compared to the general population. Patients with SLE, 
PSV, JDM and SSc all have high rates of early onset atherosclerosis, premature 
cardiovascular events and coronary disease [27-32]. The link between rheumatoid 
arthritis and cardiovascular morbidity has been unequivocally established in historical 
cohorts [33-36]. As much as 50% of premature deaths in this population is mainly due to 
increased cardiovascular disease [33, 34, 37]. The reasons for the high CVD prevalence 
are multifactorial. Patients with CIRD carry more traditional unfavorable cardiovascular 
risk factors and have disease-related risks through several mechanisms including 
autoantibodies, autoantigen expressions, autoreactive lymphocytes, epigenetic 
mechanisms, and inflammatory components driving the formation, progression and 
rupture of atherosclerotic plaques, and activation of the coagulation system [38-42]. 
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The endothelium has received much attention because it is believed that endothelial 
dysfunction is one of the earliest steps involved in the process of atherogenesis. The 
endothelium produces nitric oxide, an endothelium-derived relaxing factor that promotes 
vasodilation and reduces vascular resistance in response to physiological changes, and 
also possesses anti-inflammatory and anti-thrombotic properties at the endothelial blood 
interface [43, 44]. Deficiency in the production and bioavailability of nitric oxide resulting 
from endothelial damage leads to impairment of endothelial-dependent vasodilation, 
which has been proven to be an independent risk factor of cardiovascular events [45, 
46]. 
 
The imbalance between endothelial damage and repair may also lead to increased 
cardiovascular events [47]. Endothelial progenitor cells (EPC) are believed to participate 
in repairing the damaged endothelium and maintaining the integrity of the vascular lining. 
Several studies have reported that inflammation negatively influences the mobilization 
and differentiation of EPC [48-51]. In many rheumatic diseases, decreased numbers and 
functionally altered EPCs have been described [52-56].  
 
There remains considerable uncertainty about the effect of immunosuppressive drugs on 
the risk of CVD in patients with rheumatic disease. Certain immunosuppressive agents 
have been associated with reduced risk or mortality related to CVD [57-59], while others 
showed potential cardiovascular toxicities [60]. Various traditional and unconventional 
cardiovascular risk factors are potentiated by the adverse effects of immunosuppressive 
drugs.  
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1.4 IMMUNOSUPPRESSIVE THERAPY 
The treatment of inflammatory rheumatic diseases is a major challenge for 
rheumatologists primarily because the etiology of the majority of rheumatic disease is 
incompletely understood, involving complex interactions among genetics, environment 
and host factors, and the heterogeneity of disease phenotypes. We know for a fact that 
aberrations in immune function are involved in disease pathogenesis and present at all 
stages of disease. Hence, current therapeutic approaches are largely to restrict 
immunologic function thereby reducing inflammatory damage.  
 
Systemic immunosuppressive agents used in CIRD include, but are not limited to, 
glucocorticoids, cyclophosphamide, cyclosporine, tacrolimus, methotrexate, and 
mycophenolate mofetil [61, 62]. These agents are effective in inducing and maintaining 
remission of many autoimmune/rheumatic disease. The five-year survival of patients 
with rheumatic disease has improved dramatically thanks to the use of 
immunosuppressants [63-65]. The initial drugs of choice used in treating disease, like 
corticosteroids and cyclophosphamide, are largely non-specific. They interfere with 
major immune pathways and in a variety of cells. However, this also means more 
unwanted effects are associated with use of these agents. Recently, more target-specific 
drugs are becoming available which have potential to reduce the toxicity of 
immunosuppressant drugs. However, not all patients respond to all 
immunosuppressants, and these medications do have potentially serious side effects.  
 
1.5 MYCOPHENOLIC ACID 
Mycophenolic acid (MPA) is the active drug of mycophenolate mofetil (MMF). It was first 
discovered by Gosio in 1893 as a fermentation product of Penicillium culture which was 
later confirmed by others [66, 67]. MPA was found to have antimicrobial and antifungal 
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properties but its anti-infective properties are modest [67, 68]. Through the early 
experiments, it was discovered that MMF has antimitotic properties raising interest that it 
might be a good agent for immunosuppressive therapy [69]. Currently, it is widely used 
in transplantation for prophylaxis of organ rejection. Taking advantage of its effects on 
the immune system, MPA/MMF is frequently prescribed by rheumatologists to and found 
to be effective in treating systemic inflammatory diseases such as SLE, polymyositis, 
dermatomyositis and SSc. 
 
1.5.1 PHARMCOKINETICS  
MMF is rapidly absorbed and hydrolyzed to the active compound MPA by plasma and 
tissue esterase after oral administration. It is highly bound to albumin (97 to 99%) in 
patients with normal renal and liver function. The plasma concentration of MPA rises 
rapidly and peaks within 1 hour of ingestion, followed by a second peak at 6 to 12 hours 
due to enterohepatic circulation. The mean apparent half-life (t1/2) of MPA in the systemic 
circulation is approximately 9 to 17 hours. The majority of MPA is metabolized in the liver 
(and a small proportion by other tissues, including intestine and kidney) through a phase 
II glucuronidation process mediated by UDP glucuronosyltransferases (UGT). The major 
metabolite of MPA is the pharmacologically inactive 7-O-glucuronide metabolite 
(MPAG), which is produced by UGT1A9. Two other metabolites—MPA-acyl-glucuronide 
(AcMPAG) and MPA-phenyl-glucoside (glucoside-MPA) – are also produced [70, 71]. 
(Figure I-1). Inactive phenolic glucuronide is excreted in both urine via active tubular 
secretion and bile via multi-drug resistance protein 2 (MRP-2). Biliary-excreted MPAG 
can be deconjugated back to MPA during enterohepatic recirculation which contributes 
to 40% of area under the plasma concentration-time curve [70]. MPAG is present at a 
much higher concentration than MPA but it does not have any immunosuppressive 
activity. AcMPAG was known as pharmacologically inactive however, some investigators 
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have demonstrated that it has an inhibitory effect on lymphocyte proliferation in vitro and 
could possibly be associated with toxic effects [72]. The therapeutic concentrations of 
MPA after oral administration vary between 1 to 10 μM (0.32 to 3.2 mg/L). 
 
Figure I-1. Mycophenolic Acid Pathway.  
Simplified pathway of how MMF and MMS prodrug are absorbed, distributed, 
metabolized and excreted in the system. 
MMF = mycophenolate mofetil, MMS = mycophenolate sodium, MMA = mycophenolic 
acid, UGT = UDP glucuronosyltransferase. Figure adapted from Perez-Aytes et. al. 
(2007) [73]. 
 
1.5.2   MECHANISM OF ACTION 
MPA inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH) causing the 
depletion of the intracellular guanine triphosphate (GTP) supply [74]. IMPDH catalyzes 
the NAD-dependent formation of the parent compound of purine nucleotides, xanthine 
monophosphate (XMP) from inosine-5’-monophosphate (IMP). This reaction is 
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irreversible and a committed step (rate-limiting step) to the synthesis of guanine 
monophosphate (GMP) [69]. Figure I-2 illustrates how MPA disrupt purine synthesis.  
 
Figure I-2. Pathway of purine biosynthesis. 
MPA inhibits IMPDH, which directly causes depletion of the guanine nucleotides GMP, 
GDP, dGDP, GTP, and dGTP). 
MPA = mycophenolic acid, IMPDH = inosine monophosphate dehydrogenase, GMP = 
guanosine monophosphate, GDP = guanosine diphosphate, GTP = guanosine 
triphosphate, dGDP = deoxyguanosine diphosphate, dGTP = deoxyguanosine 
triphosphate, HGPRT = hypoxanthine guanine phosphoribosyltransferase, PRPP = 
phosphoribosylpyrophosphate. Figure adapted from Hermann et. al. (2004) [75]. 
Most cell types have the capacity to synthesize guanosine nucleotides by the IMPDH 
and salvage pathways, but lymphocytes are dependent upon de novo synthesis [69]. It is 
therefore believed that MPA selectively inhibits the proliferation of human T and B 
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lymphocytes. However, MPA affects many other cell types and does so by non-IMPDH 
dependent pathways since they are not reversible by guanosine administration [76-79]. 
 
1.5.3    EFFECTS OF MPA ON ENDOTHELIAL CELLS 
MPA reduces cytokine-induced production of nitric oxide, and cytokine-mediated 
expression of VCAM-1, ICAM-1, E-selectin, tumor necrosis factor-alpha (TNF-α), 
interleukin (IL)-1 and IL-6 [79-81]. It has been shown to inhibit endothelial migration, 
proliferation and angiogenesis in vitro [82-84]. In addition, MPA reduces endothelin-1 
expression and increases prostacyclin release [82]. 
 
1.6 ENDOTHELIUM 
The endothelium is a single layer of cells that line the entire vascular system from the 
arteries to the smallest capillaries. Endothelial cells (EC) are found on the luminal 
surface of blood vessels where they are metabolically active. Endothelium not only 
functions as a physical barrier to agents, but it also regulates vascular tone and 
remodeling, transports various molecules, synthesizes proteins and secretes vasoactive 
agents and cytokines that are critical in maintaining homeostasis [85]. The properties of 
the endothelium vary among different sites of the vasculature reflecting different 
functions within the body [86, 87]. 
 
1.6.1 NEW VESSEL FORMATION  
EC have the capacity to proliferate and migrate to denuded areas either by angiogenesis 
or vasculogenesis [88-90]. This begins at the embryonic stage during organ 
development and continues throughout life to remodel structures and repair damaged 
vessels. In general, cell division is rapid early in life to keep pace with growth and then 
slows in adulthood.  
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Blood vessels can form via two processes. In angiogenesis, new capillaries arise from 
the wall of existing vessels through a series of coordinated events in response to specific 
signals [91]. Vasculogenesis, on the other hand, is in situ formation and growth of 
primitive vessels from primitive angioblasts [91, 92]. It was believed that de novo vessel 
formation is limited to early embryogenesis and does not occur after the vascular system 
is established. It was not until two decades ago that the concept of postnatal 
vasculogenesis as a form of neovascularization was introduced. Human CD34+ cells 
isolated from circulating peripheral blood and bone marrow differentiated into endothelial 
cells in vitro and also in vivo that later contributed to neovascularization in the host 
animal [88, 93]. These cells were called endothelial progenitor cells (EPC) and were 
found to be present in sites of tissue ischemia and injury. The discovery of EPC sparked 
great interest in terms of vessel and tissue renewal, and remains a popular area of 
research in understanding disease pathogenesis and regenerative medicine. 
 
1.6.2 IDENTIFICATION OF CIRCULATING ENDOTHELIAL CELLS INVOLVED IN 
VESSEL REPAIR 
EPC are broadly referred to as cells capable of differentiating into endothelial cells that 
contribute to the formation of new blood vessels. EPC were first described by Asahara et 
al. based on surface antigen expression, morphology and ability to incorporate into 
vessels [93]. This vague definition led to multiple cell types being called EPC, resulting in 
contradictory findings as to their precise role in health and disease. Hematopoietic and 
myelomonocytic cells that exhibit endothelial cell properties e.g., expression of 
endothelial cell surface markers and colony forming activity, when exposed under the 
right condition have been incorrectly labeled as EPC [94-96]. Therefore, stringent 
classification and definition is the first necessary step to eliminate confusion and to 
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permit the field to advance. Experts in this discipline addressed this issue recently and 
proposed standards to confirm an endothelial progenitor phenotype [97]. EPC phenotype 
and function should be identified using detailed immunophenotyping, potency assays, 
and clear separation from hematopoietic angiogenic cells which are not endothelial 
progenitors. 
 
Distinguishing EPC from mature functional endothelial cells and hematopoietic cells 
based on cell surface marker expression alone is challenging because these categories 
of cells commonly share many markers. It is imperative to show that cells have the 
capacity to differentiate into mature functional endothelial cells in vitro and in vivo 
requiring the assessment of a variety of parameters including morphology, behavior, in 
situ localization, and both gene and protein expression [94, 98-100].  
Endothelial cells grow in monolayers in vitro, become growth inhibited on reaching 
confluence, and exhibit a “cobblestone” morphology [101]. Some EPCs are selected 
based on their adherence properties and they grow as monolayers with morphology 
similar to endothelial cells but morphology alone is not a useful indicator to show actual 
differentiation into mature endothelial cells.  
The ability to identify endothelial cells based on their increased metabolism of acetylated 
low density lipoprotein (Ac-LDL) was examined using the fluorescent probe 1,1'-
dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanine perchlorate (Dil-Ac-LDL) [102]. In this 
assay, ECs are highly fluorescent compared to pericytes and smooth muscle cells when 
incubated with the compound. This uptake assay has been used to demonstrate EC 
properties of EPC but the problem is that Ac-LDL is also taken up by monocytes and 
macrophages, making them phenotypically indistinguishable from EPC [95]. 
Lectins are carbohydrate-binding proteins of nonimmune origin that can bind to a wide 
variety of glycoproteins bearing the same carbohydrate motif and have been widely used 
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to interpret the sugar codes on glycoproteins [103]. A lectin called Ulex Europaeus 
Agglutinin Type I (UEA-1) has specific affinity for the 1-fucose moieties found on 
endothelial cells [104]. However, monocytes, fibroblasts, megakaryocytes and other 
blood cells bind to UEA-1 and thus UEA-1 binding cannot solely be used as a marker for 
EPC [95, 105, 106]. 
 
Tube formation assays are performed to assess the functional properties of endothelial 
cells. Many cells are capable of lining up to each other and coalesce on a two-
dimensional (2D) surface to form a cord network, but only ECs undergo tube formation 
creating a lumen. This can only be observed in a three-dimensional (3D) system [107]. 
Many of the putative EPC form cords using a 2D matrix but have not been shown to form 
3D tubes. Collagen and fibrin are components of the most widely used matrix in 3D 
assays that mimic components of the extracellular matrix to which EC are constantly 
exposed to in vivo. Other cell types typically do not form tubes in such matrices; thus, 
the endothelial potential of putative progenitors can be reliably tested in these 3D 
systems. 
 
The de novo formation of functional vessels in vivo is the most rigorous test to determine 
whether a specific cell population can contribute to postnatal neovascularization [108]. 
This can be done with intravenous injection into injured animals, direct injection into 
injured tissues, and implantation of the cells of interest within a matrix or tumor 
environment followed by careful imaging analysis using a microscope capable of 
visualizing 3D vascular structures and identifying whole singe cells.  
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Once EPC have incorporated into host vessel in vivo, the gene/protein expression 
indicative of mature, functional EC must be determined to demonstrate that a phenotypic 
change has taken place to confirm vasculogenesis. 
 
Several distinct population of circulating cells were found to be involved in repairing the 
endothelium:  the colony forming unit-Hill (CFU-Hill), circulating angiogenic cells (CAC) 
and endothelial colony forming cells (ECFC). While CFU-Hill express some endothelial 
markers and form colonies in culture, they also highly express myeloid cell markers 
(CD14, CD45, CD115). The colonies are contaminated with hematopoietic progenitor 
cells and T lymphocytes, have poor proliferative potential and are capable of 
phagocytosis [94, 96, 109]. CACs are spindle-shaped, show the same antigenic 
characteristics as CFU-Hill cells, and are contaminated with platelets that possess 
surface antigens similar to endothelial cells [110, 111].   
 
1.6.3 ENDOTHELIAL COLONY FORMING CELL (ECFC) 
ECFCs, derived from adult and umbilical cord blood, are cells that appear much later in 
culture with colonies forming between 14 and 21 days and are also called outgrowth 
endothelial cell [112]. ECFC display characteristic cobblestone morphology, express 
endothelial but not myeloid markers, are highly proliferative, and do not ingest bacteria 
[94]. ECFC form networks in vitro and blood vessels de novo in vivo that inoculate with 
nearby host vessels and become part of the systemic circulation of the host animal [94, 
113, 114]. They exhibit all the characteristic of a true progenitor cell and thus can aptly 
be called EPC. The differences between CFU-Hill, CAC and ECFC are shown in figure I-
3 and table I-1. 
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Figure I-3. Different EPC culture methods. 
Culture of CFU-Hill, Method A, scale bar = 100 µm) is a 5-day process wherein non-
adherent MNCs give rise to the EPC colony. CAC, Method B, scale bar = 200 µm) are 
the adherent mononuclear cells of a 4- to 7-day culture procedure. They typically do not 
display colony formation. ECFCs, Method B, scale bar = 400 µm) are derived from 
adherent MNCs cultured for 7–21 days in endothelial conditions and colonies display a 
cobblestone morphology. [Images were collected using a Zeiss Axiovert 2 inverted 
microscope with x10/0.25 Ph1 CP-ACROMAT (CFU-Hill), x32/0.40 Ph1 LD-
ACROSTIGMAT (CAC), or x5 CP-ACHROMAT/0.12 Ph0 (ECFC) objectives. Images 
were acquired using a SPOT RT color camera (Diagnostic Instruments, Sterling Heights, 
MI, USA) with the manufacturer’s software. Images cropped and scale bars added in 
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Adobe Photoshop version 8.0.] CFU-Hill = Colony-forming unit – Hill, MNC = 
mononuclear cell, EPC = endothelial progenitor cell, CAC = Circulating angiogenic cell, 
ECFC = Endothelial colony forming cell. Figure modified and adapted from Prater DN et 
al. (2007) [115]. 
 
 CFU-Hill CAC ECFC 
Clonal proliferative status - - + 
Replicating ability - - + 
In vitro tube formation ± ± + 
In vivo de novo vessel formation - - + 
Homing to ischemic sites in vivo + + + 
Paracrine augmentation of angiogenesis + + ± 
Phagocytosis of bacteria + + - 
Non-specific esterase expression + + - 
Phenotypic appearance CD34±,  
CD133+,  
VEGFR2+,  
CD45±,  
CD14±,  
CD115+,  
CD31+,  
ALDHbright,  
acLDL 
uptake,  
UEA-1 lectin 
binding, 
 
CD34±,  
CD133+,  
VEGFR2+,  
CD45±,  
CD14±,  
CD115+,  
CD31+,  
ALDHbright,  
acLDL 
uptake, 
UEA-1 lectin 
binding, 
 
CD34+,  
CD133-,  
VEGFR2+,  
CD45-,  
CD14-,  
CD115-,  
CD31+,  
ALDHbright/lo, 
acLDL 
uptake,  
UEA-1 lectin 
binding, 
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 eNOS,  
von 
Willibrand+ 
 eNOS,  
von 
Willibrand+ 
 eNOS,  
von 
Willibrand+ 
 
Table I-1. Characteristics of cells in the commonly used assays of “EPC” identification. 
Adherent cells that display the function are indicated by (+), those that do not display the 
function by (-), and if the literature provides conflicting evidence (±). Only the ECFC and 
progeny display the full properties one would attribute to an EPC. CFU-Hill = Colony-
forming unit – Hill; CAC = Circulating angiogenic cell; ECFC = Endothelial colony 
forming cell; VEGFR2 = vascular endothelial growth factor receptor 2; ALDH = aldehyde 
dehydrogenase; UEA-1 = Ulex europeaus agglutinin-1; acLDL = acetylated low density 
lipoprotein; eNOS = endothelial nitric oxide synthase. Table modified and adapted from 
Hirschi et al. (2008) [116]. 
 
1.7 EPC IN RHEUMATIC DISEASE 
The role of EPC in maintaining vascular homeostasis is a relevant topic in rheumatology 
because of the prominent vascular complications that is associated with chronic 
rheumatic inflammation. Altered peripheral blood numbers and altered function of EPCs 
have been described in patients with inflammatory rheumatic disorders like systemic 
sclerosis, SLE and vasculitides [117-119]. 
 
SLE has been associated with depleted [119-122], normal [52] or increased peripheral 
EPC numbers. Studies on SSc showed decreased peripheral EPC numbers in some 
studies [19, 123] but others found increased EPCs in the circulation compared to healthy 
controls [18, 117]. In dermatomyositis, circulating EPC were present in lower numbers 
and they displayed decreased ability to differentiate into mature EC [54]. There are 
conflicting reports regarding the presence and role of circulating EPC in SSc. Increased 
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numbers of EPC have been demonstrated in one study [124]; however in another the 
numbers were significantly reduced [19].  
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CHAPTER II 
2.1 INTRODUCTION 
Vascular dysfunction is widely reported to be present clinically and pathologically in 
patients with CIRD. Endothelial dysfunction occurs early in rheumatic disease and is 
associated with an increased risk of premature CVD over time. Both traditional and 
disease-specific risk factors contribute to the cardiovascular morbidity. There is good 
evidence that endothelial repair is impaired in vasculitis and this may contribute to 
vascular dysfunction and damage. EPCs have been identified as important players in 
maintaining vascular homeostasis. ECFC are endothelial cell precursors with clonal 
proliferative potential that display the ability to spontaneously form blood vessels upon 
implantation into host tissues, therefore are true EPCs that can be potential targets in 
understanding vasculitis or vasculopathy pathogenesis and recovery in the setting of 
autoimmune or rheumatic disease. 
 
MPA is widely used off-label to treat many rheumatic conditions. The duration of MPA 
use is unpredictable but the majority of patients remain on this drug for several years or 
even decades. Despite good disease control, the higher cardiovascular risk of patients 
with rheumatic disease remains high. The frequent and chronic use of MPA in treating 
diseases associated with an increased risk for developing vascular dysfunction and 
consequent cardiovascular disease, raises the question as to the effects of MPA on 
ECFC number and function. 
 
2.2 OBJECTIVES AND HYPOTHESIS  
It is evident that the endothelium is not merely a target for injury, but rather, it is actively 
involved in the localization and propagation of inflammation and perhaps also the 
initiation of autoimmune responses. Patients with CIRD have significant endothelial 
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dysfunction which may be partly attributed to impaired endothelial repair from off-target 
effects of immunosuppressive drugs.  
 
The purpose of this study is to determine the effect of MPA, a potent 
immunosuppressive drug commonly used in rheumatology, on blood vessel or 
circulating endothelial cell colony populations and their function.  
The hypothesis is that MPA diminishes the proliferative potential and vasculogenic 
function of human ECFC.  
 
The hypothesis was tested by: 
• Determining the effects of MPA on ECFC proliferation, migration and 
vasculogenic function 
• Determining the mechanisms by which MPA exerts effect on ECFC 
 
2.3 MATERIALS AND METHODS 
2.3.1 CULTURE OF HUMAN ECFC 
Human umbilical cord blood samples from healthy term newborns, gestational age 37-40 
weeks, were collected in CPD solution. Blood was diluted with Hanks balanced salt 
solution (HBSS, Invitrogen, Grand Island, NY) in equal parts. It was then layered on top 
of Histopaque 1077 (ICN, Costa Mesa, CA), centrifuged for 30 minutes at room 
temperature and washed with complete endothelial growth medium-2 (EGM-2) medium 
to isolate mononuclear cells (MNC). EGM-2 was made by combining endothelial basal 
medium (EBM, Cambrex, Walkersville, MD) and EGMTM-2 BulletKitTM comprising of: 
human epidermal growth factor (hEGF), human basic fibroblast growth factor (hFGF-β), 
insulin-like growth factor (R3-IGF-1), vascular endothelial growth factor (VEGF), heparin, 
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ascorbic acid and hydrocortisone, and supplemented with 10% (v/v) fetal bovine serum 
(FBS, Hyclone, Logan, UT), 2% penicillin/streptomycin and 0.25 μg/mL amphotericin B. 
MNCs were re-suspended in EGM-2 medium and seeded onto six well plates precoated 
with type I rat tail collagen (BD Biosciences, Bedford, MA) and cultured in 37oC with 5% 
CO2 humidified incubator for 24 hours. Non-adherent cells and debris were aspirated 
and EGM-2 medium was added to each well. Medium was changed daily for seven days 
and then every other day until the first passage. Once confluent, cells were detached 
using TrypLETM Express (Gibco), counted and either plated onto 75-cm2 tissue culture 
flasks pre-coated  with type 1 rat tail collagen for further passage, or frozen at -80oC for 
future use. 
 
2.3.2     FREEZING AND THAWING OF ECFC 
Confluent cells were detached from the plate and centrifuged at 220x g for 5 minutes. 
Supernatant was discarded and cells were re-suspended in complete EGM-2 with 10% 
(v/v) dimethyl sulfoxide (DMSO, Sigma-Aldrich) a density of 1x106 cells/ml cryovial. Cell 
vials were cooled in a Nalgene 5100 Cryo freezing container at -80°C. For longer term 
storage, cells were stored in liquid nitrogen. 
 
Frozen cells were thawed at room temperature. Once almost defrosted, FBS was added 
and the solution transferred into a conical tube, centrifuged and re-suspended in 
complete EGM-2. Cells were transferred to tissue culture flasks or plates and allowed to 
adhere at least overnight. Cells were cultured as described above. 
 
 
 
 
21 
2.3.3 MPA 
MPA stock solution was made by dissolving MPA powder (C17H20O6, MW: 320.3; Selleck 
Chemicals) in 0.6% methanol before diluting in culture medium to the desired final 
concentrations. 
 
2.3.4     GUANOSINE 
Guanosine powder (Sigma-Aldrich) was dissolved in EGM-2 media to make 1000 µM 
concentration and then diluted to desired final concentration. Stock solution was made 
fresh with each experiment. 
 
2.3.5    EFFECTS OF MPA ON HUMAN ECFC PROLIFERATION: CELL COUNTING 
BY TRYPAN BLUE EXCLUSION 
Equal densities (1x104 cells) of ECFC were seeded onto 24-well culture plates and 
cultured with EGM-2 medium with or without MPA at 0.1, 1, 2.5 and 5 micromolar (µM) 
concentrations. Cells were detached, centrifuged and re-suspended in medium. An 
aliquot was counted in a hemacytometer in the presence of 0.4% Trypan blue dye 
(Thermo Fisher Scientific) at 1:2 dilution after 24, 48 and 72 hours of incubation. Viable 
cells were identified as Trypan excluding cells. Cell percentage was calculated by 
dividing the number of viable cells over total cells and multiplying by 100.  
 
2.3.6     EFFECTS OF MPA ON HUMAN ECFC PROLIFERATION: SINGLE CELL 
ASSAY FOR CLONAL PROLIFERATIVE POTENTIAL 
Single EC were sorted using a FACSAria Sorter (Becton Disckinson, San Jose) and 
placed into each well with complete EGM-2 medium in a 96-well tissue culture plate pre-
coated with collagen. Wells were examined the day after plating to endure the presence 
of a single cell per well. Culture medium was replaced with complete EGM-2 medium 
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with or without MPA at various concentrations, and then incubated at 37oC with 5% CO2 
for 13 days with two media changes. On day 14, cells were fixed with 4% 
paraformaldehyde (PFA, Thermo Fisher Scientific) and stained with 4',6-diamidino-2-
phenylindole stain (DAPI, Sigma-Aldrich). Each well was then examined for colony 
formation using a Zeiss Axiovert 25 CFL inverted microscope with a 10x CP-
ACHROMAT/0.12 NA objective. For quantitative analysis, wells that had at least 2 EC 
were scored and examined further by visual counting. The colonies were classified as 
EC clusters (2 to 50 cells), low proliferative potential (LPP)-ECFC (51 to 2,000 cells), 
and high proliferative potential (HPP)-ECFC (more than 2,000 cells).  
 
2.3.7     EFFECTS OF MPA ON HUMAN ECFC PROLIFERATION: 
CARBOXYFLUORESCEIN SUCCINIMIDYL ESTER (CFSE) 
CFSE (Molecular Probes, Eugene, OR) lyophilized powder was dissolved in DMSO and 
stored as aliquots at -20oC. CFSE-DMSO stock solution was diluted in pre-warmed 
phosphate-buffered saline (PBS) to make a 5 µM concentration. Cultured ECFCs were 
trypsinized, centrifuged, re-suspended in PBS dye solution and incubated for 20 minutes 
at room temperature protected from light. 7.5-15x104 CFSE-stained cells were cultured 
in complete EGM-2 medium at defined concentrations of MPA at 0, 1, 3, 5 and 7 days. 
After appropriate time of culture, cells were harvested, fixed with 4% PFA, and stored at 
4oC. On day 7, the CFSE mean fluorescence intensity (MFI) of all harvested samples 
was measured using flow cytometry (BD FACS Canto II) and analyzed using FlowJo 
software (TreeStar). To account for differences in CFSE staining between replicates, the 
MFI of the day 0 sample was used as an internal control. Thereby, the MFI of each 
sample was normalized by dividing it by the MFI of the day 0 control. Results are plotted 
on a log2 scale to visualize the doubling nature of cell proliferation. The data represent 
averages of 4 biological replicates. 
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2.3.8   EFFECTS OF MPA ON HUMAN ECFC MIGRATION: IN VITRO SCRATCH 
ASSAY 
4x104 cells per well were plated in triplicate onto a 12-well plate and cultured in complete 
EGM-2 medium. Upon reaching 70-80% confluence, a single straight line through the 
cell monolayer was made by scraping the surface using a sterile p1000 pipette tip. Cells 
were washed once with PBS to remove cell debris and replaced with medium with or 
without MPA. The plates were placed in the incubator at 37oC for 6 to 24 hours. Images 
were taken at various time points after the scratch and we measured the average 
distance between the lines. Image J software (NCBI) was used to quantify gap distance. 
 
2.3.9   EFFECTS OF MPA ON CAPILLARY NETWORK FORMATION: TWO-
DIMENSIONAL (2D) MATRIGEL ASSAY 
Growth-factor reduced Matrigel (BD Bioscience) was thawed at 4oC overnight. The gel 
was allowed to polymerize at 37oC for 30 minutes before use. EC were trypsinized and 
re-suspended in EGM-2 media. Cells were seeded at 1x104 cells per well in triplicate 
onto 96-well plates coated with 50 μL of growth-factor reduced Matrigel. Complete EGM-
2 medium with or without MPA were added to the well and incubated at 37oC with 5% 
CO2 for 6 hours. Three images were taken from each well at 10x magnification using a 
Zeiss Axiovert 25 CFL inverted microscope with a 10x CP-ACHROMAT/0.12 NA 
objective. Total cord length and average cord area were calculated using ImageJ 
software (NCBI). 
 
2.3.10   EFFECTS OF MPA ON CAPILLARY NETWORK FORMATION: THREE-
DIMENSIONAL (3D) COLLAGEN ASSAY 
Reagents for 3D collagen matrix were purchased from GeniPhys (Zionsville, IN) unless 
otherwise specified. To make the matrix, stock oligomer was diluted in 0.01 N hydrogen 
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chloride (HCl) and neutralized according to the manufacturer's recommendations to 
achieve a final oligomer concentration of 1.56 mg/ml (250 Pa matrix stiffness) before 
adding 10% human platelet lysate (SALK, Graz, Austria). Matrix was maintained in 
solution at 4oC until used. 1x105 ECFCs (60 μL) were suspended in the collagen matrix. 
The collagen-cell suspensions were plated onto 96-well culture plate wells and allowed 
to polymerize at 37oC for 30 minutes before covering with MPA treated and control 
culture medium. Cells were incubated at 37oC with 5% CO2 with daily medium change. 
The cultures were checked under a microscope every 24 hours until lumenized vessel-
like structures were formed and identified. After three days, cells were fixed with 4% PFA 
and stained with 0.1% toluidine blue O dye (Thermo Fisher Scientific). Three images 
were taken at a uniform depth from the surface of the matrix using a Zeiss Axiovert 25 
CFL inverted microscope. Average cord area was quantified using ImageJ software 
(NCBI). 
 
2.3.11   CELL CYCLE ANALYSIS WITH 5'-BROMO-2'-DEOXYURIDINE (BrdU) 
ECFC (3-5x105) were exposed to either vehicle control or MPA 1 μM. After 3 days, cells 
were treated with BrdU labeling reagent (Invitrogen) for 1 hour at 37oC with 5% CO2. 
Cells were stained using Alexa Flour 488 mouse anti-BrdU (Invitrogen) for 90 minutes at 
room temperature and 7-AAD (Life Technologies) for 15 minutes at room temperature. 
Samples were analyzed by flow cytometry on the LSRII 407nm laser and a minimum of 
10,000 events were recorded per sample. The percentage of cells at the G0/G1, S and 
G2/M phases of the cell cycle were analyzed using FlowJo Single Cell Analysis Software 
vX.0.6.  
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2.3.12   APOPTOSIS 
The effect of MPA on ECFC death by apoptosis was examined using annexin V-
fluorescein isothiocyanate (FITC) and propidium iodide (PI) analysis by flow cytometry. 
5-35x104 cells were plated and treated with varying concentrations of MPA for 7 days 
with one media change. Cells were collected and incubated for 15 minutes at room 
temperature with annexin V-FITC (BD Pharmigen) and PI (BD Pharmigen) in the dark, 
and immediately analyzed on a flow cytometer (BD Biosciences San Jose, CA). Data 
were processed using FlowJo software (TreeStar), determining the percentage of 
apoptotic cells. 
 
2.3.13   SENESCENCE: CELL MORPHOLOGY 
7.5x105 cells were plated on T75 tissue culture flask and allowed to attach overnight. 
Cells were then exposed to complete EGM-2 with or without MPA. Images were taken 
after 3 days. 
 
2.3.14   SENESCENCE: SENESCENCE- ASSOCIATED BETA-GALACTOSIDASE (SA-
β-GAL) STAINING 
To determine MPA effect on cellular senescence, SA-β-gal assay was performed using a 
Senescence Detection kit (BioVision, Milpitas, CA) according to the manufacturer’s 
instructions. Upon senescence, the lysosomal mass is increased, leading to production 
of higher levels of β-galactosidase [125]. Cells were washed twice with PBS, fixed using 
the supplied fixing solution for 10-15 minutes, washed again with PBS, stained with SA-
β-gal solution (X-gal in dimethylfomamide 20 mg/ml plus staining supplement) and 
incubated overnight at 370C without CO2 protected from light. After 24 hours, staining 
solution was discarded and the cells were overlaid with 70% glycerol. To quantify SA-
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beta-gal activity, the percent of positively stained blue cells (senescent cells) versus total 
cells were counted (500-600 cells).   
 
2.3.15   SENESCENCE: GENE MARKERS 
ECFCs were grown to 70-80% confluence in T75 tissue culture flasks after thawing. The 
media was removed, cells washed in PBS, trypsinized and re-suspended in complete 
EGM-2 culture medium. Equal density of cells was plated on 6-well tissue culture plates 
and incubated at 37oC overnight to allow cell attachment. Media was removed, washed 
in PBS once, replaced with EGM-2 media with or without MPA and incubated for 3 days. 
 
2.3.15.1     ISOLATION OF RNA 
RNA was isolated from ECFC to examine the effect of MPA on expression of genes that 
are associated with senescence. Total mRNA was extracted from the cell using 
RNAeasy Micro Kit (Qiagen). All reagents and plastic-ware used in the isolation of RNA 
were molecular grade and RNAse-free. The concentration and purity of the extracted 
RNA was measured using a Nanodrop 2000 (Thermo Scientific, Wilmington, DE).  
 
2.3.15.2     REVERSE TRANSCRIPTION  
Complementary DNA (cDNA) was synthesized from RNA by reverse transcription and 
used as a template for PCR amplification performed on a LifeEco thermal cycler. 500 ug 
of total RNA was reverse transcribed using SuperScript™ III First-Strand Synthesis 
System (Invitrogen). Each sample was incubated with Oligo-dT primers and 10mM of 
dNTP mix at 65°C for 5 minutes, then placed on ice for at least 1 minute. To each tube, 
2μl dithiothreitol (DTT) (100mM), 4μl MgCl2 (25mM), 2μl 10x buffer, 1μl RNaseOUT (40 
U/µL) enzyme and 1µL of SuperScript III RT (200 U/µL) enzyme were added. The 
extension step was carried out at 50°C for 50 minutes and the reaction terminated at 
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85°C for 5 minutes. Then 1 µL of RNase H was added and incubated at 37°C for 20 
minutes. cDNA synthesis reaction was used immediately for polymerase chain reaction 
or stored at -20°C until used.  
 
2.3.15.3     REAL TIME POLYMERASE CHAIN REACTION (qRT-PCR) 
qRT-PCR analysis was performed using SYBR Green PCR Master Mix (Applied 
Biosystems, UK) and real time detection on 7500 Real-Time PCR machine (Applied 
Biosystems, UK). Each 10 µL PCR reaction was carried out in triplicate, and contained 1 
µL cDNA, SYBR Green and the appropriate forward and reverse primers (5nM each). 
PCR was carried out according to the following protocol: 95°C for 10 minutes then 40 
cycles of denaturation (95°C for 15 seconds), annealing (60°C for 60 seconds) and 
extension (60°C for 60 seconds).  
 
Relative gene expression was calculated using the 2−ΔΔCt method normalized to beta-2-
microglobulin mRNA expression levels. 
ΔCt: ratio = 2Ct (GOI) – Ct (Ref gene)  
ΔΔCt: ratio = 2-ΔCt (sample of interest) – ΔCt ( control sample) 
 
The following primers (Table II-1) were used: 
Gene Sequence (5'->3') 
Human p16INK4a Forward: GGGGGCACCAGAGGCAGT 
 Reverse: GGTTGTGGCGGGGGCAGTT 
Human p21WAF Forward: AGTCAGTTCCTTGTGGAGCC 
 Reverse: GACATGGCGCCTCCTCTG 
Human p27Kip1 Forward: TAATTGGGGCTCCGGCTAAC 
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 Reverse: GAAGAATCGTCGGTTGCAGGT 
Human β-2-microglobulin Forward: CTCCGTGGCCTTAGCTGTG 
 Reverse: TTTGGAGTACGCTGGATAGCCT 
 
Table II-1. List of primers 
 
2.3.16   SENESCENCE: p53 PROTEIN LEVEL 
2.3.16.1     CELL LYSATE PREPARATION 
Cells were cultured with and without MPA for 3 days. After removing the media, plates 
were washed with ice cold PBS and cells were scraped into cell lysis buffer mix. Tubes 
containing the lysate buffer mixture were placed on a shaker at 300 rpm for 10 minutes 
at room temperature. Total protein concentration was determined by bicinchoninic acid 
(BCA) method. 
 
2.3.16.2     ELISA 
p53 (Total/Phospho) InstantOne ELISA Kit (Affymetrix) was used to specifically detect 
endogenous levels of total (tot) and phosphorylated (ph) p53 protein generation 
according to the manufacturer’s instructions. 0.2-0.3 mg/ml protein lysates were added 
to each assay well followed by prepared tot-p53 and ph-p53 antibody cocktail (capture 
antibody and detection antibody regents). After a 1 hour incubation at 300 rpm, wells 
were washed 3x with wash buffer before adding detection reagent. The reaction was 
terminated with stop solution after 15 minutes incubation with shaking at 300 rpm and 
the absorbance immediately measured spectrophotometrically at 450 nm. 
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2.3.17   GUANOSINE AND MPA 
The consequence of IMPDH inhibition by MPA is a reduction in guanine nucleotide 
pools. We tested whether MPA exerts its effect on ECFC IMPDH enzyme activity by 
measuring whether the addition of guanosine can reverse the suppressive cell growth 
effects of MPA. The following experiments were performed as described above: cell 
counting by trypan blue exclusion, senescence gene markers and p53 ELISA. 
 
2.3.18   STATISTICAL ANALYSIS  
Unless otherwise mentioned, all experiments were performed at least three times with 2-
3 technical replicates for each assay. Data are presented as the means±SD. Two-tailed 
Student's t-test or Fisher's exact test were used to assess for significance of differences 
between two groups. All statistical analyses were implemented using Graphpad Prism or 
Microsoft Excel software. 
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2.4 RESULTS 
2.4.1    MPA INHIBITS ECFC PROLIFERATION 
To determine whether endothelial cells are affected by MPA, human cord blood derived 
ECFCs were cultured with increasing MPA concentrations through the usual patient 
targeted therapeutic range and examined for cell proliferation. The cell number 
increased at least 4-fold after 48 hours and 10-fold after 72 hours of culture in untreated 
control cells and cells exposed to 0.1 μM MPA concentration. There was no significant 
change in viable cell counts of ECFC cultured in 1, 2.5 and 5 μM MPA concentrations at 
either timepoint (Figure II-1.), suggesting a complete block in cell proliferation.  
   
 
Figure II-1. ECFC number after exposure to MPA measured by cell counting.  
Cell growth curve was evaluated using trypan blue staining to measure viable cells at 24, 
48 and 72 hours. 1-5 μM concentration of MPA inhibited cell proliferation (n = 3). Results 
represent the mean ± SD.*** P < 0.001 compared to vehicle. MPA = mycophenolic acid 
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ECFC display a hierarchy of proliferative potential that can be discriminated on a single-
cell level [112]. Single cell assay was performed to evaluate the effect of MPA on ECFC 
clonogenic potential. MPA concentrations (0.1-1 μM) were selected based on results 
from the cell proliferation assay with Trypan blue staining. At 0.1 μM MPA concentration, 
89.5% (±2.0%, NS) of the single endothelial cells underwent ≥1 cell division. We 
observed that 40.1% (±8.2%, NS) of the total cells that divided had formed colonies of 
51-2,000 cells per well (LPP-ECFC) and 55.7% (±16%, NS) formed >2,000 cells (HPP-
ECFC that display self-renewal potential). At 1 μM MPA concentration, 70% (±8%, 
p<0.05) of the single cells plated divided and the majority of cells were restricted to 
forming small EC clusters (92.9%±3.5%, p<0.005). No HPP-ECFCs were seen to 
emerge from either 0.56 μM or 1 μM MPA treated cells. MPA treatment resulted in a 
dose-dependent decrease in overall colony formation (Figure II-2). The loss of HPP-
ECFC at the higher doses suggests that the most primitive cells are more susceptible to 
MPA effects.  
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Figure II-2. Clonogenic potential ECFC following MPA treatment.  
(A) Percentage of single cord blood-derived ECFC undergoing at least one cell division 
14 days after MPA treatment (n = 3). (B) Percentage of cell clusters, LPP-ECFCs and 
HPP-ECFC 14 days after MPA treatment using single cell analysis (n = 3). Results 
represent the mean ± SD. *P <0.05, **P<0.005 compared to vehicle. ECFC = endothelial 
colony forming cell, EGM = endothelial growth medium, MPA = mycophenolic acid, LPP-
A 
B 
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ECFC = low proliferative potential – endothelial colony forming cells, HPP-ECFC = high 
proliferative potential-endothelial colony forming cells. 
ECFC proliferation was measured using CFSE staining. The CFSE dye stains 
intracellular proteins and is evenly distributed in dividing progeny cells after cellular 
division. As such, the rate of decrease of CFSE MFI among cultured cells is proportional 
to their rate of proliferation. We used flow cytometry to measure the MFI of CFSE-
stained ECFC during 7 days of culture at increasing doses of MPA. As expected, cells 
cultured with vehicle or 0.1 μM MPA regularly divided and displayed diminished MFI over 
the 7 days culture. We observed significantly greater CFSE MFI retention (indicative of 
lack of cell division) in ECFC treated with MPA 0.5 and 1 μM MPA compared with ECFC 
treated with vehicle control (Fig II-3). 
Figure II-3. Effect of MPA on ECFC proliferation measured by CFSE.  
Proliferation of ECFC in the absence or presence of MPA (0.1, 0.5 and 1 μM) measured 
after 1, 3, 5 and 7 days by a FACS-based CFSE dilution assay. While 0.1 μM MPA did 
not impact ECFC division, MPA at higher concentrations significantly diminished ECFC 
division (n = 4). Results represent the mean ± SD. **P<0.005 compared to vehicle. 
CFSE = carboxyfluorescein succinimidyl ester, MPA = mycophenolic acid 
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2.4.2   MPA DELAYS ECFC MIGRATION 
ECFC migration into a denuded vessel is a vital process in wound healing. To determine 
whether MPA inhibits migration of ECFC, we performed an in vitro scratch assay. A line 
was drawn along the leading edges of each cell front at time 0 hour and 15 hour and we 
measured the gap distance as percentage of un-occupied area at 15 hour divided by 0 
hour exposure to media with and without treatment. Untreated cells completely closed 
the gap when examined after 15 hours, but a cell-free area is clearly visible in the MPA-
treated (1 μM) cells (Figure II-4). The lag in gap closure observed after drug treatment 
can be attributed to delayed cell migration.  
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Figure II-4. MPA treatment impairs ECFC migration.  
Cell migration was assessed using an in vitro scratch assay with and without MPA 
treatment. Representative phase-contrast images of ECFC incubated with vehicle 
control media at time 0 hour after wounding (A) and closure of the gap after 15 hours 
(B). ECFC incubated with 1 μM MPA at time 0 hour after wounding (C) and presence of 
a gap after 15 hours (D). Quantification of gap distance after 15 hours of incubation (E). 
Gap fully closed in vehicle treated wells while a gap is still clearly visible in cells treated 
with 1 μM MPA (25.8% ± 10%, *p<0.005) compared to vehicle (n = 4 to 6). MPA = 
mycophenolic acid, ECFC = endothelial colony forming cells 
 
2.4.3   MPA REDUCES ECFC FUNCTION 
Normal EC reparative function is also important in maintaining adequate vascular 
homeostasis. In the 2D assay, cells align with each other and form cord networks. The 
addition of MPA 2.5 μM concentration significantly reduced average cord area and total 
cord length by 29% (0.082 mm2±0.009, P = 0.037) and 54% (5.45 mm2±0.75, P = 0.026) 
respectively, compared to untreated cells (Figure II-5). In the 3D assay, single cells are 
suspended in gel and form vascular structures that emerge through a process of 
E 
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cytoplasmic vacuolation [126]. The 3D assay is thus likely to be more representative of 
vessel formation in vivo than the 2D assay. The capillary-like structures with patent 
lumens were measured. Treatment with 1 μM MPA reduced tube formation to very 
rudimentary tubular structures. The average vascular area of cells exposed to MPA 1 μM 
and 2.5 μM concentrations was significantly smaller than the untreated cells by 78% 
(0.017 mm2±0.004, P = 0.0006) and 88% (0.009 mm2±0.0006, P = 0.003) respectively, 
compared to the untreated cells (Figure II-6). These data suggest that MPA inhibits the 
functional vasculogenic properties of ECFC. 
 
Figure II-5. Diminished ECFC vasculogenic function after MPA treatment (2D). 
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Representative photomicrographs (magnification, x10) of ECFC following no treatment 
(vehicle) or treatment with 2.5 µM MPA in 2D assay (A). 2D Matrigel assay showed that 
there is decreased average total cord length (B) and cord area after MPA treatment. *P 
<0.05 compared to vehicle (n=3). ECFC = endothelial colony forming cells, 2D = two-
dimensional, MPA = mycophenolic acid, mm = millimeter. 
 
 
 
 
Figure II-6. Diminished ECFC vasculogenic function after MPA treatment (3D). 
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Representative photomicrographs (magnification, x10) of ECFC following no treatment 
(vehicle) or treatment with 2.5 µM MPA in 3D assay (A). 3D collagen assay showed 
decreased total vessel area after MPA treatment (B). *P <0.05, **P <0.005 compared to 
vehicle (n=3). ECFC = endothelial colony forming cells, 3D = three-dimensional, MPA = 
mycophenolic acid, mm = millimeter 
 
2.4.4    MPA CAUSES ECFC CELL CYCLE ARREST 
ECFCs were incubated with 1 µM MPA or vehicle. The effect of this treatment on 
progression through cell cycle analysis was analyzed using flow cytometry. MPA 
treatment led to 40-50% increase in the number of cells in the G1 phase, and the 
frequency of cells in the S phase fell by more than 50% (Figure II-7). 
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Figure II-7. Cell cycle analysis using BrdU and 7-AAD staining 
Representative flow cytometry gating strategy to measure cell cycle progression of 
ECFC without (A) and with (B) MPA treatment. Quantitation of cell cycle analysis using 
flow cytometry data (n=3). *P<0.01. Abbreviations: MPA = mycophenolic acid 
 
2.4.5   MPA DOES NOT CAUSE ECFC APOPTOSIS 
To investigate whether the effect observed on cell proliferation was due to cell death, an 
apoptosis assay using flow cytometry was performed. The percentage of annexin V-
negative/PI-negative (viable cells), annexin V-positive (undergoing early death) and PI-
positive (dead or necrotic cells) cells cultured with or without 1 μM MPA were not 
statistically different (Fig II-8). This result indicates that the inhibition of proliferation after 
MPA treatment was not due to enhanced cell death. 
Figure II-8.  No effect on apoptosis after adding MPA 
Flow cytometric analysis of cells labelled with Annexin-V–PI double staining showing the 
number of viable (PI-/AnnV-), early death (AnnV+) and apoptotic (PI+) cells. Results 
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expressed as means ± SD (n=3). MPA = mycophenolic acid, PI = propidium iodide, 
AnnV = annexin V, n.s. = not significant       
 
2.4.6   MPA INDUCES PREMATURE ECFC SENESCENCE VIA p21/p53 PATHWAY 
Senescence is another mechanism by which cell growth and proliferation is inhibited. In 
order to determine whether MPA induces senescence in ECFC, SA-β-gal staining was 
used. Several human cells express β-galactosidase, histochemically detectable at pH 6, 
upon senescence in culture. This marker is expressed by senescent, but not 
presenescent, quiescent and terminally differentiated cells [125]. There is a significant 
dose-dependent increase in SA-β-gal positive cells (8-fold and 12-fold after 3 days of 
treatment with 0.5 μM and 1 μM MPA, respectively). This effect was more pronounced 
after 5 days of MPA treatment (Figure II-9).  
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Figure II-9. MPA treated cells have increased SA-β-gal staining  
(A) Photomicrograph of SA-β-gal staining of ECFC cultured with vehicle and 1 μM for 5 
days. Blue color (arrow) indicates cellular senescence. (B) Quantification of SA-β-gal 
staining. At least 500 cells per individual sample were counted. The number of SA-β-
Gal-positive cells treated with 0.5 and 1μM MPA concentrations was significantly greater 
than untreated cells. *P <0.05 compared to vehicle (n=3). SA-β-gal = senescence 
associated-beta galactosidase, MPA = mycophenolic acid. 
 
To identify the mechanism by which MPA enhances susceptibility of ECFC to undergo 
senescence, we determined the expression of p16INK4a, p21WAFand p27Kip1, cyclin 
dependent kinase (CDK) inhibitors and known senescence-associated inducers of cell 
cycle arrest. The expression of p21WAF in cells exposed to 1 μM MPA (11.45±1.84) 
increased significantly compared to untreated cells (6.77±2.67), but no significant 
difference in p16INK4a and p27Kip1 expression (Figure II-10) was found in these groups.  
 
 
 
 
 
 
 
 
Figure II-10. MPA treated cells have higher senescence related p21WAF gene 
expression. 
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Gene expression of p16INK4A, p21WAF and p27Kip1 in untreated and treated cells 
normalized to B2M products. Results represent the mean ± SD compared (n = 3). *P < 
0.05 relative to vehicle control. MPA =mycophenolic acid, B2M = beta-2-microglobulin 
 
Since p53 directly induces p21WAF and is a key regulatory component of stress-inducible 
cell growth arrest, we assessed whether MPA-treated cells displayed increased p53 
activation. By comparing the ratio of UV absorbance between phosphorylated (ph)-p53 
and total (tot)-p53. A significantly higher level of p53 phosphorylation (activated state) 
was observed in the MPA treated cells compared to controls (Figure II-11).  
 
Figure II-11. MPA treated cells have higher phosphorylated p53 expression. 
Phosphorylation of p53 normalized to total p53 in cell lysates determined using ELISA 
method. Results represent the mean ± SD compared (n = 3). *P < 0.05 relative to 
vehicle control. OD = optical density, ph-p53 = phosphorylated p53, tot-p53 = total p53, 
MPA = mycophenolic acid. 
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These results show that MPA-treated cells become highly senescent, and imply that 
p21WAF gene upregulation is dependent on p53 activation to drive ECFC into senescence 
as a result of MPA treatment. 
 
2.4.7   GUANOSINE RESTORES ECFC PROLIFERATION AND PREVENTS ECFC 
SENESCENCE 
The consequence of IMPDH inhibition by MPA is a reduction in guanine nucleotide pools 
[127]. We tested whether MPA exerts its effect on ECFC IMPDH enzyme activity by 
measuring whether the addition of guanosine can reverse the suppressive cell growth 
effects of MPA. Guanosine at 50 or 100 μM alone was neither mitogenic nor inhibited 
cell growth. 100 μM guanosine together with 1μM MPA completely restored ECFC 
proliferation after 48 hours and 72 hours. We observed similar effects in cells exposed to 
medium containing 50 μM guanosine and 1 μM MPA but cell proliferation rescue was 
17% lower (n.s.) than 100 μM of guanosine (Figure II-12). Thus, guanosine 
supplementation was sufficient to rescue ECFC from the anti-proliferative effects of MPA 
in a dose dependent fashion, consistent with the known mechanism of action of MPA on 
cells. 
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Figure II-12. Guanosine reversed MPA’s inhibitory effect on cell proliferation. 
Cell proliferation using the trypan blue exclusion assay shows that guanosine is not 
cytostatic or inhibitory (A), and that addition of guanosine rescues ECFC proliferation in 
a dose dependent manner (B). Results represent the mean ± SD compared (n = 3). ***P 
<0.001 relative to vehicle. MPA = mycophenolic acid. 
Based on the ability of guanosine to rescue ECFC proliferation, we tested whether 
guanosine would rescue the cells from senescence. The addition of 100 μM guanosine 
decreased p21WAF gene expression to levels that were similar to those seen in control 
cells (Figure II-13).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure II-13. Guanosine reversed MPA’s inhibitory effect on senescence gene 
expression. 
Relative fold expression of senescence associated gene markers p16INK4a, p21WAF and 
p27KiP1. Results represent the mean ± SD compared (n =3). *P < 0.05 relative to vehicle. 
MPA = mycophenolic acid. 
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Accordingly, guanosine completely restored p53 activation to control levels despite the 
presence of 1μM MPA (Figure II-14).  
Figure II-14. Guanosine reversed MPA’s inhibitory effect on p53. 
Phosphorylation of p53 normalized to total p53 level in cell lysates. Results represent the 
mean ± SD compared (n =3). *P < 0.05 relative to vehicle. MPA = mycophenolic acid, 
OD = optical density, ph-p53 = phosphorylated p53, tot-p53 = total p53. 
 
These results imply that the cytostatic effect of MPA in ECFC is through guanosine 
depletion via IMPDH inhibition, and the addition of exogenous guanosine rescues MPA-
induced inhibition in cell proliferation and senescence. 
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2.5 Discussion 
MPA has potent anti-angiogenic properties and exerts a dose-dependent inhibition of 
ECFC proliferation in vitro by driving cells towards senescence. MPA treatment severely 
impairs the ability of ECFC to form blood vessels in vitro and decreases ECFC cellular 
migration.  
 
The in vitro results are consistent with previously reported data that MPA/MMF treatment 
at 1-100 µM concentrations inhibits proliferation and blocks angiogenesis in vivo in 
various types of mature EC [83, 84, 128]. From this work, we conclude that MPA exerts 
direct effects on proliferative endothelial cell populations that have reparative and 
regenerative potential. Results of studies evaluating EPC number and function in 
patients with CIRD, including systemic lupus erythematosus, systemic scleroderma and 
primary systemic vasculitis, are inconsistent [25-28]. One reason is because there are 
no EPC-specific cell markers and hence, there is difficulty in accurately defining EPC 
identity. Many studies purportedly examining EPC number and function were in fact 
analyzing proangiogenic hematopoietic cells, which are circulating bone marrow-derived 
cells that plays a role in neovascularization of damaged tissue but do not fully integrate 
as true endothelial cells into the remodeled endothelium [29-32]. Recent work has 
highlighted the multi-cellular network of proangiogenic cells and vascular endothelial 
cells required to effectively repair damaged endothelium [32]. Early work from our group 
showed that ECFC display all features of the originally defined endothelial progenitor 
cell, and the infusion of ECFC into pre-clinical animal models of hind limb ischemia, 
myocardial infarction and retinal ischemia enhanced vascular recovery [19, 33-35]. Due 
to ECFC’s vessel forming potential and the importance of maintaining EC homeostasis, 
the inhibitory effect of MPA observed in this study highlights the concern for vascular off-
target toxicity of this immunosuppressive agents. Further clinical studies are required to 
48 
determine first, the intrinsic behavior of ECFC in patients with CIRD and second, 
whether the drugs exert similar in vivo effects on ECFC in rheumatic patients maintained 
on immunosuppressive therapies. Since these cells are rare in the peripheral circulation 
[19], analysis will require sampling a high volume of blood from patients which is very 
challenging in the pediatric population. It is important to note that we started with a 
concentration range of MPA (1-5 µM) that includes clinically relevant and targeted serum 
trough concentration of 1-3.5 µg/mL (3.3-11.5 µM).The concentration range was reduced 
by 10-fold in subsequent experiments due to the potent inhibitory effects of MPA on 
ECFC in vitro. This raises concern that MPA at current therapeutic doses in patients may 
possess potential vascular toxicity especially with the notable narrow therapeutic index 
of MPA and large intra- and inter-individual variation in both MPA plasma concentrations 
and levels of IMPDH activity [36, 37].  
 
We showed that MPA-treated ECFC in vitro display senescent-like features such as lack 
of proliferation, cell cycle arrest, and increased SA-ß-galactosidase activity. The p53/p21 
signaling pathway known to be a critical regulator of cell survival is also activated in a 
senescence process that subsequently leads to vascular dysfunction [38]. We 
demonstrated a higher level of expression of the CDK inhibitor p21WAF and p53 
activation. In the cardiovascular literature there is accumulating evidence that implicates 
endothelial cell senescence in the initiation and progression of atherosclerosis. Vascular 
senescence had been identified in human atherosclerotic lesions and is thought to be an 
important contributor to the pathogenesis of age-associated conditions like heart failure 
and diabetes [39-41]. Many adult and childhood-onset systemic rheumatic diseases are 
complicated by endothelial dysfunction, premature atherosclerosis and increased CV 
disease that are not fully explained by traditional risk factors and the risks persist even 
after disease control is clinically attained [2, 5]. Immune related cells undergoing 
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senescence may be a desired effect to control overactive lymphocytes, or unwanted 
breakdown in self-tolerance favoring the development of autoimmune disease [42-44].  
The possibility that senescent changes in EC may contribute to the pathophysiology and 
increased CV morbidity of rheumatic disease is plausible and has not been fully 
examined. Oxidative stress, pro-inflammatory cytokines, enhanced telomere shortening 
with inadequate repair, and the destructive influence of senescence-associated 
secretory phenotype are some of the hypothesized mechanistic processes potentially 
involved [45-47]. It is beyond the scope of this study to investigate the specific regulatory 
mechanisms and pathways that occur after MPA treatment of ECFC. However, it will be 
an interesting area to pursue in future research. In our work, MPA caused senescence 
without induction of apoptosis in ECFC, a finding in contrast to what has been observed 
in T cells [78, 129]. 
 
We added guanosine to assess for IMPDH independent GTP synthesis indirectly. 
Exogenous guanosine supplementation restored ECFC proliferation and interestingly, it 
reversed the senescence effect of MPA at a transcriptional and functional level. This 
finding proves that despite the ability of EC to scavenge free purine and/or purine-
containing ribonucleosides and deoxyribonucleosides to maintain critical cellular levels 
of these essential metabolites [50], the guanine salvage pathway is unable to 
compensate for the low GTP pool to prevent cell growth arrest in MPA treated cells.  
 
In conclusion, our study demonstrates that MPA has a potent inhibitory and anti-
angiogenic effect on EC. Here, we provided a plausible molecular mechanism in the 
senescence pathway not previously demonstrated. MPA drives ECFC to go into 
premature senescence and thus is likely to have pathophysiologic significance in the 
early atherosclerosis seen in CIRD. The direct short- and long-term clinical consequence 
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of these effects on cardiovascular health and morbidity are unknown. This warrants a 
better understanding of how other immune suppressive drugs disrupt vascular 
homeostasis and might contribute to endothelial dysfunction. In the clinic, MMF and 
MPA are favored by many rheumatologists due to their steroid-sparing properties, 
reversible side effect profile, ease of administration and renal protective effects [130-
132]. However, recognition and understanding of the mechanisms of this endothelial 
toxicity will be crucial for optimal patient management. This study highlights the need for 
more translational research to gain insight into mechanistic links among endothelial cell 
biology, systemic inflammation, and vascular injury and repair in patients with rheumatic 
disorders. Further knowledge can usher the discovery of better and safer 
immunosuppressive therapies and drug regimens in treating patients with systemic 
rheumatic disease that optimize desired effects while minimizing unwanted drug 
toxicities, the basis for individualized therapy. 
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CHAPTER III 
3.1 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) 
3.1.1   EPIDEMIOLOGY OF SLE  
SLE is an autoimmune disease of unknown etiology defined by chronic inflammatory 
processes and the production of a wide range of antibodies against self-antigens. It has 
an incidence of 2 to 7.6 per 100,000 people per year and a prevalence of 15 to 50 per 
100,000 population per year. It primarily affects women and has a female: male ratio of 
9:1 [133]. Clinical presentation is highly variable; the disease follows a relapsing and 
remitting course. SLE is diagnosed based on fulfilling at least 4 out of the 11 criteria 
proposed by the American College of Rheumatology (ACR) in 1997 (Table III-1) or 4 of 
the 17 SLICC/EULAR classification criteria, with at least one clinical and one 
immunologic criterion (Table III-2). 
Clinical Laboratory 
Malar rash Hematologic disorder  
    - hemolytic anemia,  lymphopenia, leukopenia, 
thrombocytopenia  
Discoid rash Immunologic disorder  
    - anti-DNA, anti-Sm, anti-phospholipid Ab  
Photosensitivity Antinuclear antibody  
Oral ulcers 
 
Arthritis  
 
Serositis  
 
Renal disorder 
 
Neurological disorder  
 
      Table III-1. The 1997 Updated ACR Classification Criteria for SLE 
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Clinical Features Immunologic Features 
Acute cutaneous lupus 
(maculopapular lupus rash, malar 
rash, photosensitive lupus rash) 
Anti-nuclear antibody  
Chronic cutaneous lupus (discoid 
rash, mucosal lupus) 
Anti-DNA 
Oral or nasal ulcers Presence of Anti-Sm  
Non-scarring alopecia Anti-phospholipid antibody 
Arthritis or synovitis in ≥ 2 joints Low complements (C3, C4, CH50) 
Serositis  Direct Coombs’ test 
Renal disorder (urine protein or RBC 
casts) 
 
Neurological disorder (seizures, 
psychosis, others) 
 
Hemolytic anemia  
Leukopenia or lymphopenia (without 
an identifiable cause) 
 
Thrombocytopenia (without an 
identifiable cause) 
 
       Table III-2. The 2012 SLICC/EULAR Classification Criteria for SLE 
 
3.1.2   RENAL INVOLVEMENT IN SLE 
Lupus nephritis (LN) is a common manifestation of SLE. The clinical manifestation may 
be subtle, suspected when proteinuria and/or hematuria is present. A definitive diagnosis 
of LN is established with a kidney biopsy. LN has a profound negative impact on kidney 
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and overall survival across age-groups [134]. Immune-complex LN is described 
pathologically using the 2003 International Society of Nephrology/Renal Pathology 
Society (ISN/RPS) nomenclature. It classifies LN on the basis of where immune 
complexes accumulate in glomeruli, the presence or absence of mesangial or 
endocapillary proliferation, the overall extent of glomerular involvement (focal or diffuse) 
and glomerular injury (global or segmental), and whether glomerular injury is active 
(inflammatory) or chronic (sclerotic) (Table III-3) [135]. In general, the proliferative 
classes are treated aggressively, whereas non-proliferative classes can be managed 
more conservatively. Aggressive immunosuppressive therapy has improved the 
prognosis of SLE patients with renal disease considerably, but 5-20% still progress to 
end stage renal disease (ESRD) within 10 years following the diagnosis of nephritis 
[136]. Patients with LN have a higher standardized mortality ratio and die earlier than 
SLE patients without LN [137]. 
 
Although immune-complex–mediated glomerulonephritis is the most common cause of 
kidney disease in SLE, there are other mechanisms that result in renal injury. Renal 
vascular complication is another striking feature of lupus and this could include 
uncomplicated vascular immune deposits, non-inflammatory necrotizing vasculopathy, 
thrombotic microangiopathy, true renal vasculitis, thrombotic thrombocytopenic purpura, 
antiphospholipid antibody syndrome and renal vein thrombosis [4]. 
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Table III-3. International Society of Nephrology/Renal Pathology Society (ISN/RPS) 
2003 classification of lupus nephritis. Adapted from Weening et. al. (2004) [135]. 
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3.1.3   CARDIOVASCULAR DISEASE (CVD) IN SLE 
Mortality in SLE follows a bimodal pattern. Urowitz et. al. in 1976 showed that early 
death is related lupus disease activity and infection, and this is followed by a second 
later peak mostly due to CVD [138]. This pivotal study made physicians aware that SLE 
is associated with premature atherosclerosis, coronary artery disease, myocardial 
infarction and stroke. Several papers from other research groups later showed varying 
risk estimates but a consistent trend of significantly increased risk of CVD in patients 
with SLE compared to healthy controls [139-141]. It is known that CVD risk factors of 
obesity, hypertension, and dyslipidemia is more prevalent in SLE patients. However, 
traditional CV risk factors do not completely account for the heightened CV risk [142], 
therefore it is likely that lupus-related risk factors like chronic inflammation, cytokines 
and organ damage, are an important contributors and may play a more vital role in CV 
risk development in patients with SLE. Despite a significant reduction in mortality among 
lupus patients over the last 5 decades with current 5-year survival of more than 85%, it is 
interesting to note that lupus-related mortality has decreased in all categories except 
CVD [140, 141].  
 
3.1.4   CHILDHOOD-ONSET SLE (cSLE) 
Childhood-onset SLE, with disease onset prior to 16 years of age, represents 15-20% of 
SLE patients [143]. Children and adolescents generally have more severe illness at 
initial presentation, more aggressive disease course, higher rates of organ involvement, 
accrue greater disease damage over time, and have increased need for long-term 
immunosuppressive medication [144, 145]. 
 
Renal disease is more severe and more common in cSLE. It occurs in 50 to 75% of all 
cSLE patients, mostly within the first 2 years after diagnosis, with 18 to 50% of them 
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progressing to ESRD. Several cohort studies report a higher percentage of pediatric 
patients who have biopsy-proven renal disease, with a trend toward significantly more 
proliferative nephritis than adults [145-147].  
 
Given their lifelong exposure to atherogenic risk factors, children and adolescents with 
SLE are at particularly high risk for developing premature atherosclerosis. Studies have 
shown that compared to healthy controls, there is evidence of structural and functional 
endothelial dysfunction and damage in cSLE [148-151]. 
 
3.2 ENDOTHELIAL CELL (EC) DAMAGE LEADING TO TISSUE INJURY  
Steroids and immunosuppression are the cornerstone in management of lupus. While 
advances in immunosuppressive treatment have decreased organ damage and life-
threatening events in SLE, there is still no cure for SLE and not all patients respond to 
immune suppression. This reflects incomplete understanding of disease pathogenesis 
and the need find new treatment target. 
 
In the kidneys, EC interact with mesangial cells, podocytes, renal tubular cells and 
pericytes, all of which are important for cell development, homeostasis, function and 
survival through release of cytokines, chemokines and soluble factors. When any one of 
the renal components is damaged, it is shown that ECs are also affected [152-154].  
Disturbance of angiogenesis reported in LN is associated with endothelial dysfunction 
including a decrease in the ratio of pro-angiogenic Ang1/anti-angiogenic Ang2, 
downregulation of the angiogenic factor FGF-2, an increase in the VEGF inhibitor 
ADAMTS-1, and alterations in endothelial nitric oxide synthase [155-157]. 
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EC are mainly affected in SLE-associated CVD. High type I interferon (IFN) production 
and the pro-inflammatory environment seen in SLE patients affect the endothelial cell 
population, and appears to play a critical role in tilting the balance towards endothelial 
damage and impaired vascular repair [120, 158]. Other known factors toxic to 
endothelial cells including activated inflammatory cells, immune complexes, expression 
of costimulatory molecules, generation of neutrophil extracellular traps (NETs), lupus-
related autoantibodies, oxidative stress, and dyslipidemia, likely tip the balance towards 
endothelial dysfunction and propensity to develop premature cardiovascular disease in 
lupus patients. 
 
3.3 PRISTANE INJECTION AS A MURINE MODEL OF SLE DISEASE 
Pristane (2,6,10,14 tetramethylpentadecane or TMPD) is a hydrocarbon found in many 
plants, marine organisms, crude oil and is a common constituent in mineral oil used in 
food, cosmetic and pharmaceutical products. When pristane is given parenterally to non-
autoimmune prone mice, it results in the generation of autoantibodies and development 
of clinical manifestations associated with SLE [159]. It had been repeatedly shown that 
ANA, anti-ssDNA, anti-dsDNA, anti-Su, anti-Sm, anti-RNP, anti-histone and anti-
ribosomal P, auto-antibodies common in human SLE, develop within 1-6 months after 
intraperitoneal injection of pristane [159, 160]. Treated mice develop features of lupus 
syndrome such as arthritis, serositis, glomerular hypercellularity, glomerular immune 
complex deposition and proteinuria. A unique feature of this murine model is that it is the 
only one reported to have the interferon (IFN) signature characteristic of human SLE. IN 
humans, SLE is associated with excess and dysregulated production of type I IFN that is 
reflected in overexpression of IFN-I-stimulated genes. This pattern is known as the 
interferon signature and it is clinically important since a correlation has been found with 
disease activity, renal involvement, and the presence of autoantibodies [161]. Peripheral 
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blood mononuclear cells from mice injected with pristane overexpress interferon 
signature genes; moreover, signaling via the IFN alpha receptor is central to the 
pathogenesis of lupus in this animal model [162, 163].  
 
3.4 VASCULAR ENDOTHELIAL STEM CELL (VESC) AND VESSEL REGENERATION 
Although it is clear that a subset of EC has clonal proliferative potential and contributes 
to postnatal vasculogenesis, we do not know where these cells arise from. It is also 
unclear how the EC pool is replaced after injury and maintained during homeostasis, i.e., 
health. More recently, there is evidence to suggest that endothelial stem cells give rise to 
mature EC and reside in the vascular wall. Stem cells have an extensive capacity to 
proliferate, differentiate into mature tissue-specific cells, and self-renew, enabling them 
to repopulate recipients after cellular transplantation [164, 165]. Much effort has been 
devoted to isolating and characterizing adult stem cells that give rise to the vascular 
endothelium including: side population method which is a flow cytometry technique used 
to obtain stem cells based on the dye efflux properties of the ATP-binding cassette 
(ABC) transporters [166-168], and use of cell surface protein markers like c-Kit, protein 
C receptor and CD157 [169-171]. However, the side population technique is based on 
function rather than a cell surface markers, making it difficult to be used to prospectively 
identity these cells in vivo. Existing markers are inadequate because they are either non-
specific, are not detected in other tissues, or not shown to be present in human EC. 
Despite progress in discovering new stem cell markers, better methods are needed for 
identifying postnatal vascular endothelial stem cells (VESC). 
 
3.5 ABCG2 TRANSGENIC MOUSE MODEL 
The ABC family drug transporter Abcg2 has been associated with the side population 
phenotype and stem cell activity in various organs [172-174]. The Yoder lab explored the 
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Abcg2 as potential VESC marker in a murine system using the Abcg2 transgenic mouse 
model. 
 
Genetic recombination is the most widely used labeling system in mouse models. This 
technology utilizes tissue or cell-specific promoters that control Cre recombinase 
enzyme expression which when activated, promote a reporter transgene by the excision 
of a loxP-flanked transcriptional stop cassette [175]. Using an inducible system like this, 
Cre is activated only in the presence of an anti-estrogen or progesterone receptor agent. 
This allows tracking the fate of cells over time [176]. Fatima et al. generated a lineage 
tracing mouse model based on an allele that co-expresses both Abcg2 and a CreERT2 
(Estrogen Receptor Type 2) expression cassette (Abcg2CreERT2) to track Abcg2-
expressing cells and their progeny in many organs [177]. We bred mice transgenic for 
tamoxifen inducible Abcg2CreERT2 with ROSATdTomato mice to generate ABCG2TT 
mice that identify Abcg2-expressing EC in the murine system. Unpublished data from 
Yoder lab reveals that Abcg2-expressing EC play a role in new blood vessel formation in 
the heart, lungs, muscle, retina and skin. More importantly, these endothelial cells fulfill 
all the criteria of VESC including clonal proliferative potential, ability to self-renew and 
contribution to multiple blood vessel compartments (artery, vein, capillary) upon 
transplantation via fate mapping analysis. This system will allow the investigation of the 
characteristics of resident VESC in different tissues following various types of injury. 
Particularly, this model will allow us to investigate how chronic rheumatic inflammatory 
disease (CIRD) like SLE and relevant immunosuppressive treatments impact the nature 
and functions of EC with reparative and regenerative potential. 
 
I hypothesize that kidney RVESC display differential reparative responses depending on 
the nature of the injury. 
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3.6 MATERIALS AND METHODS 
3.6.1 MICE 
C57BL/6 and R26R-TdTomato mice were purchased from Jackson Laboratory (Bar 
Harbor, ME, USA), housed and bred in a conventional facility at Indiana University. 
Colony of ABCG2CreERT mice used by Fatima et. al. were recovered from sperm 
provided by Dr. Sorenttino at Indiana University School of Medicine Laboratory Animal 
Resource Center. 
 
3.6.2 TAMOXIFEN INJECTION  
Tamoxifen (Sigma-Aldrich) was suspended in sunflower seed oil (Sigma-Aldrich) at 37°C 
to make a 4mg/ml solution and was stored at -20°C until use. To induce Cre expression 
in ABCG2CreERT mice, 50mg/kg tamoxifen was injected into the animals intra-
peritoneally (i.p.) at appropriate time points. 
 
3.6.3 TISSUE CELL ISOLATION  
Single cell suspensions from heart and kidney were prepared by mincing the tissue, 
digesting with 0.25% collagenase I (Stem Cell Technologies) at 37°C for 30-40 minutes, 
and disruption of cell clumps over 70 μm cell strainer (Falcon). 
 
3.6.4 FLOW CYTOMETRY 
The following conjugated antibodies were used: anti-CD31-PECy7, anti-CD45-APC, and 
Ter119-FITC were purchased from eBioscience. 1:1000 propidium iodide (PI, Sigma-
Aldrich) was added to sorting buffer before analysis to label dead cells. Cells were 
analyzed for PI-Ter119-CD45-CD31+TdTomato+ (Abcg2-expressing EC) using a 
FACSAria flow cytometer (BD Biosciences).  
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3.6.5 COLONY FORMING ACTIVITY  
CD31+ CD45- cells were sorted using Magnetic Activated Cell Sorting method. Isolated 
murine EC were re-suspended in EC culture medium (alpha-MEM with 10% FBS 
[Hyclone], 5 × 10−5 M β-mercaptoethanol [Sigma-Aldrich] and 0.5% 
penicillin/streptomycin [Gibco]), plated on a bed of OP9 stromal cells in limiting dilutions, 
and then incubated at 37°C, 5% CO2. Non-adherent cells were removed the next day 
and media changed every 3 days for 14 days. Plates were fixed with 4% 
paraformaldehyde at room temperature, washed with PBS, blocked with 2% skim milk 
(Sigma-Aldrich) in 0.1% triton (Sigma-Aldrich) PBS solution (PBSMT solution) for 30 
minutes at RT and then stained with 1:100 rat anti mouse CD31 (BD Pharmingen) 4°C 
overnight, stained with 1:200 alkaline phosphatase conjugated donkey anti rat IgG 
secondary antibody (Jackson ImmunoResearch) in PBSMT at RT for 2 hours, and lastly 
with DAPI staining. Colonies were counted and images captured using LeicaTM DM IL 
microscope with a SPOT RT3 camera. 
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3.7 PRELIMINARY RESULTS 
In neonates, 8.3±1.7% of total EC expressed TdTomato one day after tamoxifen 
injection. After 7 days, this population contributed to 36.0±11.1% of all kidney EC. In 
adult mice, 2.9±1.3% of total EC was labeled one day after a single tamoxifen injection. 
This population contributed to 15.4±2.9% of total kidney EC after 84 days (Figure III-1). 
 
Figure III-1. Kidney VESC lineage tracing. 
Quantification of lineage tracing experiment with flow cytometry shows that Abcg2-
expressing VESC contribute to kidney vessel growth in neonates (A) and tissue 
maintenance in adults (B). Data represent mean ± S.D. 
 
In neonatal heart, 18.96±5.5% of total EC expressed TdTomato one day after tamoxifen 
injection. After 7 days, this population contributed to 66.0±3.1% of all heart EC. In adult 
mice, 9.8±5.3% of total EC was labeled one day after a single tamoxifen injection. This 
population contributed to 8.3±2.9% of total heart EC after 84 days (Figure III-2). 
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Figure III-2. Heart VESC lineage tracing. 
Quantification of lineage tracing experiment with flow cytometry shows that Abcg2-
expressing VESC contribute to heart vessel growth in neonates (A) but do not change 
significantly with time when measured in adults (B). Data represent mean ± S.D. 
 
The frequency of colony formation of TdTomato labeled EC is significantly higher than 
non-labeled EC (Figure III-3 and III-4). 
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Figure III-3. Neonatal kidney EC colonies 
Representative pictures of EC colonies derived from TdTomato+ EC (top panels) and 
TdTomato- EC (bottom panels) from kidney of P7 ABCG2TT mice 24 hours after single 
tamoxifen injection. 
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Figure III-4. Colony Forming Assay of Kidney and Heart EC. 
Frequency of TdTomato+ and TdTomato- EC colonies derived from neonate (A) and 
adult (B) kidneys, compared with neonate (C) and adult (D) heart 24 hours after a single 
tamoxifen injection. Data represent mean ± S.D. *p<0.05 
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3.8 HYPOTHESIS AND AIMS 
I hypothesize that pristane-injected mice display altered endothelial features in tissues 
that show features of SLE disease in the pristane-induced murine SLE model.  
 
The aims of future study are to: 
Aim 1: Characterize the changes in EC features observed in pristane-induced lupus 
• To characterize the extent of endothelial cell injury in heart, lungs and kidneys 
o Frequency of CD45-CD31+ cells by FACS analysis at different time points 
o Microvessel density and EC frequency by histology and immunostaining 
o EC activation, inflammation and damage by gene and protein expression 
(cytokines, chemokines, adhesion molecules) 
• To assess VESC proliferative potential and activity in heart, lungs and kidneys 
o Frequency of CD45-CD31+ TdTomato+ cells 
o Colony forming activity of CD45-CD31+ TdTomato+ cells  
• To identify correlation between lupus disease activity, EC and VESC behavior 
o Measure serum antibody and interferon levels  
o Organ specific markers of lupus disease (serum creatinine, proteinuria, 
histology, markers of IFN-α activity like IP-10 and/or MCP1) 
 
Aim 2: Investigate the in vivo effects of MMF in mice 
• To assess the tissue resident VESC survival in the heart, lungs and kidneys of 
ABCG2TT mice after MMF treatment  
o Frequency and colony forming activity of CD45-CD31+ TdTomato+ cells 
using lineage tracing technique 
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o Cell cycle, apoptosis, senescence by FACS, histology, gene and protein 
expression 
• Determine the efficacy of MPA/MMF in treating pulmonary hemorrhage and 
nephritis in pristane-induced lupus 
o Serum auto-antibodies and interferon concentrations and histology 
o Tissue resident VESC proliferation and activity 
 
3.9 EXPERIMENTAL DESIGN 
 
Figure III-5. Timeline for Aim 1 
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Figure III-6. Timeline for Aim 2 
 
3.10 SIGNIFICANCE 
This study will further our understanding of the vascular involvement in SLE which is 
necessary for the development of specific cellular and targeted treatment strategies. 
Knowing how to identify these cells should make it possible to manipulate endothelial 
cell proliferation, which in turn should aid in the development of therapies to promote 
vascular repair. Knowledge obtained from this study can be extended to other rheumatic 
disease that also have prominent vasculopathy or vasculitis. We can also use the same 
system to look at how other immunosuppressive agents or combined therapies influence 
tissue-specific blood vessel endothelial health, repair and regeneration in relation to 
existing autoimmune/rheumatic disease.  
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